Navigation Links
Daiichi Sankyo Launches LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, in Japan for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Date:7/19/2011

TOKYO, July 19, 2011 /PRNewswire/ -- Building on its cardiovascular portfolio, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), is proud to announce the launch of LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in Japan. This announcement follows the first marketing approval for edoxaban 15 mg and 30 mg tablets by the Japanese Ministry of Health, Labor and Welfare in April 2011 (1), and marks the first time edoxaban is commercially available to patients in any global market.

Edoxaban is a once-daily, oral anticoagulant that specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood. Results from clinical studies supported the approval of edoxaban for the prevention of venous thromboembolism (VTE) in patients with total knee arthroplasty, total hip arthroplasty and hip fracture surgery.

"Today's launch of edoxaban marks the global debut of the medication, which is an exciting breakthrough for patients who require VTE prevention after major orthopedic surgery," said Joji Nakayama, president and CEO of Daiichi Sankyo. "Edoxaban demonstrates solid efficacy in clinical trials (2, 3) in this population of patients. Its predictable pharmacokinetic and pharmacodynamic profile allows for a convenient, once-daily dosing."

The global clinical development program for edoxaban is focused on several indications, including stroke prevention in atrial fibrillation (AF) patients, and treatment and prevention of recurrent VTE. Edoxaban is currently being assessed in the Phase III ENGAGE AF-TIMI 48 study (4), an ongoing, multinational, randomized, double-blind trial evaluating the efficacy and safety of edoxaban in preventing stroke and systemic embolic events in patients with AF. More than 21,000 patients with AF in 46 countries are being examined, making this the largest trial in this indication to date. In addition, Daiichi Sankyo is currently enrolling patients in its HOKUSAI VTE study (5)
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
3. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
4. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
5. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
6. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
7. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
10. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
11. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... YORK , Feb. 26, 2015 ... Latin America is estimated at 2.4 ... said that population growth, government insurance, newly insured ... in the region and will continue to propel ... on torresearch into the market and interviews with ...
(Date:2/26/2015)... BOSTON , Feb. 26, 2015 ... ("Columbia" or "the Company"), a specialty pharmaceutical company ... health, plans to initiate a Phase II clinical ... in women undergoing transvaginal pipelle-directed endometrial biopsy in ... pre-Investigational New Drug ("IND") submission feedback from the ...
(Date:2/26/2015)... Feb. 26, 2015  Technological advancements have ... effective, inexpensive and compact yet powerful solutions. ... small-scale, potent devices, lending momentum to the ... http://photos.prnewswire.com/prnh/20150225/177944LOGO New ... Nanomanufacturing, finds that nanomanufacturing will gain traction ...
Breaking Medicine Technology:Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 3Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 2Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 3Revolutionary Nanomanufacturing Technology to Approach Commercialization by 2020 4
... II Study Demonstrates Significant,Additional Improvement for Patients ... /PRNewswire-FirstCall/ --,Indevus Pharmaceuticals, Inc. today announced that ... for pagoclone in persistent,developmental stuttering will be ... the New Clinical Drug Evaluation Unit (NCDEU), ...
... Insomnia on Healthcare System and,Worker Productivity, SAN ... Inc. announced today that results from several,research ... and transient,insomnia were presented this week at ... APSS highlights show that,insomnia is significantly under-diagnosed ...
Cached Medicine Technology:Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 2Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 3Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 4Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 5Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 6Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 7Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 8Indevus Announces Presentation of Pagoclone Data at 47th Annual New,Clinical Drug Evaluation Unit Meeting 9Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 2Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 3Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 4Neurocrine Biosciences Announces New Research Studies Presented at,APSS Reveal Significant Under-Diagnosis of Insomnia 5
(Date:2/27/2015)... If there is one thing that drives parents into a ... at their child’s school. While head lice are not particularly ... of a nightmare for many parents as they see the ... their child’s classroom. Just when they think the problem is ... Local lice removal company, Lice Troopers , reports that ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Qualis ... management organizations, has been named a finalist in ... in recognition of outstanding commitment toward continuous improvement ... success in reducing hospital readmission rates through its ... “We are honored to receive this national recognition, ...
(Date:2/27/2015)... A fireplace can cause the average home to ... the chimney’s flue when the fireplace is not in use. ... solved with the introduction of a new small fireplace DraftStopper. ... 18" in diameter when inflated. It is quickly and easily ... damper. This size unit fits into round dampers, which are ...
(Date:2/27/2015)... The Connecticut Community for Addiction Recovery (CCAR) recently ... Drug Recovery Centers (ADRC), for its shared Recovery Oriented ... with the 2014 Commissioner’s Recognition Award by the CT ... Last year, ROES achieved the highest rate of employment ... from alcoholism and other drug addiction. More than ...
(Date:2/27/2015)... 27, 2015 Lewis Clinic Dentistry has extended ... 4PM to make its services available for patients who cannot ... from the Lewis Clinic Dentistry said, “Yes, we have extended ... on weekdays due to their busy schedules and work can ... to make more people’s lives beautiful and smiling.” He further ...
Breaking Medicine News(10 mins):Health News:Anxiety over head lice among Miami parents as surge in head lice cases reported by local lice removal company Lice Troopers 2Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:New DraftStopper from Tamarack Technologies Stops Heat Loss When Fireplace Not in Use 2Health News:Lewis Clinic Dentistry Extends Business Hours 2
... Aug. 22 , What: The American Academy of Actuaries, Public Interest Committee ... hear views on the disclosure of ... plans. The committee will use information obtained through ... board of directors on the issue is appropriately in the ...
... (Nasdaq: NXTM ), a leading manufacturer of ... of life analysis from,the FREEDOM study will be ... 2008 Annual Meeting taking place November 4-9, 2008,in ... (DHD),Improves Quality of Life (QoL) Measures, Depressive Symptoms ...
... Medicare Part B transaction ... its stores nationwide, FORT WORTH, Texas, Aug. 22 ... the retail pharmacy,industry, announced today that it will provide transaction ... state,Medicaid DME claims and clinical administration programs to Rite Aid. ...
... Group (CAHG),is proud to announce the promotion of ... eInnovation, Corbett Accel Healthcare,Group (CAHG). In his new ... Executive,Leadership Team of CAHG, and continue as Managing ... Melick is based in,CAHG,s Chicago office and will ...
... RESTON, Va.SNM and the American Society for Therapeutic ... this fall examining the impact of translational advances ... meeting, which takes place October 17-18, will bring ... young investigators in the emerging field of molecular ...
... CMS, Inc., an Elekta Company, and,worldwide leader ... received FDA 510(k) clearance for its new Atlas-Based,Autosegmentation ... distributing Atlas-Based Autosegmentation for clinical use in the,United ... spent creating and editing,patient contours, ABAS is a ...
Cached Medicine News:Health News:Actuaries to Host Forum on Public Pension Disclosures 2Health News:Actuaries to Host Forum on Public Pension Disclosures 3Health News:NxStage Announces Presentation of Data at the American Society of Nephrology's Renal Week 2008 Annual Meeting 2Health News:eRx Network to Provide Transaction Processing and Revenue Cycle Management Services to Rite Aid 2Health News:Corbett Accel Healthcare Group Announces Promotion of Geoff Melick to Executive Vice President, Interactive Marketing & eInnovation 2Health News:SNM and ASTRO team up to advance molecular imaging and cancer research 2Health News:CMS, Inc., an Elekta Company, Receives FDA 510(k) Clearance for Atlas-Based Autosegmentation Software 2
... difficile Panel is an enzyme immunoassay used ... antigen (glutamate dehydrogenase) and toxin A in ... as an aid in the diagnosis of ... of the Triage Microbiology product line, designed ...
ELISA for the detection of C. difficile toxin A in stool specimens...
... CCD cameras provide fast, accurate, reliable and ... quality at an excellent price. , , ... TOMEY TR-4000 Auto Refractor provides highly accurate ... is obtained simply by pushing a button. ...
... SP-3000 covers all needs regarding pachymetry in ... care., ,Compact design, colored touch-screen and "quick ... an "easy-to-use unit.,The wide measurement range from ... the possibility to measure very thin or ...
Medicine Products: